Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Classification of "Near-patient" and "Point-of-Care" SARS-CoV-2 Nucleic Acid Amplification Test Systems and a first approach to evaluate their analytical independence of operator activities.
Buchta C, Zeichhardt H, Badrick T, Coucke W, Wojtalewicz N, Griesmacher A, Aberle SW, Schellenberg I, Jacobs E, Nordin G, Schweiger C, Schwenoha K, Luppa PB, Gassner UM, Wagner T, Kammel M. Buchta C, et al. Among authors: griesmacher a. J Clin Virol. 2023 Aug;165:105521. doi: 10.1016/j.jcv.2023.105521. Epub 2023 Jun 8. J Clin Virol. 2023. PMID: 37302248 Free PMC article.
Converting to an international unit system improves harmonization of results for SARS-CoV-2 quantification: Results from multiple external quality assessments.
Buchta C, Kollros D, Jovanovic J, Huf W, Delatour V, Puchhammer-Stöckl E, Mayerhofer M, Müller MM, Shenoy S, Griesmacher A, Aberle SW, Görzer I, Camp JV. Buchta C, et al. Among authors: griesmacher a. J Clin Virol. 2023 Jan;158:105352. doi: 10.1016/j.jcv.2022.105352. Epub 2022 Dec 10. J Clin Virol. 2023. PMID: 36525853 Free PMC article.
Ignoring SARS-CoV-2 testing performance during COVID-19.
Buchta C, Zeichhardt H, Griesmacher A, Schellenberg I, Kammel M. Buchta C, et al. Among authors: griesmacher a. Lancet Microbe. 2023 May;4(5):e296. doi: 10.1016/S2666-5247(23)00030-7. Epub 2023 Feb 3. Lancet Microbe. 2023. PMID: 36746168 Free PMC article. No abstract available.
Three rounds of a national external quality assessment reveal a link between disharmonic anti-SARS-CoV-2 antibody quantifications and the infection stage.
Buchta C, Springer D, Jovanovic J, Borsodi C, Weidner L, Sareban N, Radler U, Müller MM, Griesmacher A, Puchhammer-Stöckl E, Wagner T, Jungbauer C, Stiasny K, Weseslindtner L. Buchta C, et al. Among authors: griesmacher a. Clin Chem Lab Med. 2023 Feb 10;61(7):1349-1358. doi: 10.1515/cclm-2022-1161. Print 2023 Jun 27. Clin Chem Lab Med. 2023. PMID: 36756735 Free article.
Design of external quality assessment schemes and definition of the roles of their providers in future epidemics.
Buchta C, Zeichhardt H, Aberle SW, Camp JV, Görzer I, Weseslindtner L, Puchhammer-Stöckl E, Huf W, Benka B, Allerberger F, Mielke M, Griesmacher A, Müller MM, Schellenberg I, Kammel M. Buchta C, et al. Among authors: griesmacher a. Lancet Microbe. 2023 Jul;4(7):e552-e562. doi: 10.1016/S2666-5247(23)00072-1. Epub 2023 May 5. Lancet Microbe. 2023. PMID: 37156257 Free PMC article. Review.
Do not blindly trust negative diagnostic test results!
Buchta C, Zeichhardt H, Osterman A, Perrone LA, Griesmacher A. Buchta C, et al. Among authors: griesmacher a. Lancet Microbe. 2024 Feb;5(2):e102-e103. doi: 10.1016/S2666-5247(23)00340-3. Epub 2023 Nov 15. Lancet Microbe. 2024. PMID: 37977166 Free article. No abstract available.
Performance of SARS-CoV-2 nucleic acid amplification testing in Austria as measured by external quality assessment schemes during 3 years of the COVID-19 pandemic: an observational retrospective study.
Buchta C, Aberle SW, Allerberger F, Benka B, Görzer I, Griesmacher A, Hübl W, Huf W, Kapiotis S, Müller MM, Neuwirth E, Puchhammer-Stöckl E, Weseslindtner L, Camp JV. Buchta C, et al. Among authors: griesmacher a. Lancet Microbe. 2023 Dec;4(12):e1015-e1023. doi: 10.1016/S2666-5247(23)00286-0. Epub 2023 Nov 15. Lancet Microbe. 2023. PMID: 37979591 Free article.
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P, Petzer V, Mündlein A, Hartmann B, Severgnini L, Winkler A, Lang T, Huynh M, Gasser K, Rüger J, Atzl M, Mink S, Fraunberger P, Schmidt S, Steiner N, Griesmacher A, Gunsilius E, Nachbaur D, Willenbacher W, Wolf D, Winder T, Benda MA. Reimann P, et al. Among authors: griesmacher a. Ann Hematol. 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2. Ann Hematol. 2024. PMID: 38436671
211 results